Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1992 Nov;11(3-4):249-66.
doi: 10.1007/BF01307181.

Tissue factor as a tumor procoagulant

Affiliations
Review

Tissue factor as a tumor procoagulant

L V Rao. Cancer Metastasis Rev. 1992 Nov.

Abstract

Tissue factor is a cell surface glycoprotein responsible for initiating the extrinsic pathway of coagulation. Many tumor cell homogenates and intact tumor cells have been shown to contain tissue factor activity. Immunohistochemical studies show that many tumors associated with Trousseau's syndrome express tissue factor on their cell surfaces. Tumor cells shed membrane fragments which carry tissue factor that can account for the activation of the clotting system. Tumor cells also produce soluble substances that can induce tissue factor expression on host cells, such as endothelium and monocytes, at sites distant from the tumor. Although, all the functional TF molecules are localized on the outer cell membrane in many tumor cells, the procoagulant activity on the intact cell surface is largely dormant and can be greatly enhanced upon cell injury or damage. Tissue factor procoagulant activity on the cell surface can be modulated by alterations in the plasma membrane without loss of cell viability. Tissue factor activity on cell surfaces is largely regulated by a plasma inhibitor, tissue factor pathway inhibitor. This inhibitor binds to both functional and non-functional tissue factor/VIIa complexes on the cell surface and prevents non-functional tissue factor/VIIa complexes from becoming functional after cell injury or lysis. Heparin, but not warfarin, therapy is effective in preventing the occurrence of devastating thrombotic events in patients with Trousseau's syndrome and the reason(s) for this are still unknown.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Haemostasis. 1991;21(4):219-39 - PubMed
    1. Mol Cell Biol. 1989 Jun;9(6):2752-5 - PubMed
    1. Blood. 1991 Jul 15;78(2):387-93 - PubMed
    1. Cancer. 1955 Sep-Oct;8(5):970-8 - PubMed
    1. Am J Med. 1985 Oct;79(4):423-30 - PubMed

Publication types

Substances

LinkOut - more resources